Trade AstraZeneca ^AZN

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows

Why Astrazeneca (AZN) Outpaced the Stock Market Today - December 20, 2024 - Zacks.com

Congestive Heart Failure Drugs Market 2030: The Future of Injectable Formulations – Express Press Release Distribution

Beijing woos AstraZeneca for investment while probe continues

AstraZeneca Faces Major Investigation in China

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZN By Investing.com

AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights | Morningstar

AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights | Valuespectrum.com

Consolidation Durvalumab Improves PFS in Unresectable Stage III NSCLC Without Progression After CRT

AstraZeneca's Alexion Inks Deal With Pan-Canadian Pharmaceutical Alliance | Markets Insider

AstraZeneca PLC (NASDAQ:AZN) Short Interest Down 8.3% in November

Rosen Law Firm Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZN | Morningstar

World Investment Advisors LLC Has $644,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Is AstraZeneca PLC (AZN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Rosen Law Firm Encourages AstraZeneca PLC Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – AZN | Morningstar

AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman | Morningstar

AstraZeneca's SWOT analysis: oncology giant's stock poised for growth By Investing.com

Drug company: We won’t charge more for ‘green’ inhalers

Short Interest in AstraZeneca PLC (NASDAQ:AZN) Drops By 8.3%

AstraZeneca announces board refresh with new directors By Investing.com

AstraZeneca Strengthens Board with New Non-Executive Director Appointments

AstraZeneca names new non-executive directors By Investing.com

Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year By Investing.com

AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Update

SpringWorks Therapeutics' SWOT analysis: stock potential amid clinical progress By Investing.com

AstraZeneca PLC (NASDAQ:AZN) Shares Sold by State Street Corp

AstraZeneca PLC ADRhedged (AZNH) To Go Ex-Dividend on December 16th

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

Peapack Gladstone Financial Corp Acquires 23,159 Shares of AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Peapack Gladstone Financial Corp

AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Verition Fund Management LLC

FDA Revokes EUA for Evusheld (tixagevimab co-packaged with cilgavimab) for the Treatment of COVID-19

Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth | Morningstar

Franklin Resources Inc. Acquires 1,522,715 Shares of AstraZeneca PLC (NASDAQ:AZN)

Kyverna Therapeutics Strengthens Leadership Team By Investing.com

Wilmington Savings Fund Society FSB Makes New Investment in AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) Holdings Lowered by Vestcor Inc

New Investigation Casts Doubt on Landmark Ticagrelor Trial | MDedge

Case: Discrimination/Pay Equity (D. Md.)

Virtu Financial LLC Takes $4.82 Million Position in AstraZeneca PLC (NASDAQ:AZN)

Advisory Resource Group Takes $946,000 Position in AstraZeneca PLC (NASDAQ:AZN)

Tracer Biotechnologies partners with AstraZeneca on ctDNA tech By Investing.com

HUTCHMED: ORPATHYS And TAGRISSO Get Breakthrough Therapy Designation In China For NSCLC | Markets Insider

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy | Morningstar

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy | Valuespectrum.com

Neoadjuvant Patritumab Deruxtecan ± Letrozole Shows Efficacy in High-Risk HR+/HER2– Breast Cancer

TD Cowen Keeps Their Buy Rating on AstraZeneca (AZN) | Markets Insider

LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial | Morningstar

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial | Morningstar

AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by National Bank of Canada FI

AstraZeneca PLC (LON:AZN) Receives Average Rating of "Moderate Buy" from Analysts

AstraZeneca’s (AZN) Struggles: Cramer’s Disappointment and Challenges in China

Groupama Asset Managment Purchases 101,225 Shares of AstraZeneca PLC (NASDAQ:AZN)

MML Investors Services LLC Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Y Intercept Hong Kong Ltd

Spatial biology captures the effects of neoadjuvant chemo-immunotherapy in lung cancer

More Biologics May Be Breaking Through for COPD | MDedge

AstraZeneca Africa staff join ‘Week of Service, highlight commitment to community sustainability

In the clinic for December 10, 2024 | BioWorld

AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC - December 10, 2024 - Zacks.com

FDA Grants Breakthrough Therapy Designation to Dato-DXd for Previously Treated EGFR+ Advanced NSCLC

Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag - December 9, 2024 - Zacks.com

In the clinic for Dec. 9, 2024 | BioWorld

Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer By Investing.com

Centiva Capital LP Buys New Shares in AstraZeneca PLC (NASDAQ:AZN)

Wexford Capital LP Sells 7,859 Shares of AstraZeneca PLC (NASDAQ:AZN)

FDA Grants Priority Review to AstraZeneca’s Imfinzi for Muscle-Invasive Bladder Cancer

AstraZeneca's Imfinzi granted Priority Review in the US for patients with muscle-invasive bladder cancer By Investing.com

AstraZeneca's Imfinzi Gains FDA Approval for New LS-SCLC Treatment

AZN : TROPION Analysis Reveals Datopotamab Deruxtecan Efficacy In Advanced EGFR-Mutated Lung Cancer

Imfinzi shows promise in bladder cancer trial, seeks FDA approval By Investing.com

FDA Approves Durvalumab for Limited-Stage SCLC | MDedge

Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ - December 6, 2024 - Zacks.com

FDA Approves AstraZeneca’s Imfinzi for Limited-Stage Small Cell Lung Cancer

Life sciences GCCs find a home in South

Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analys By Investing.com

Pfizer’s Nurtec and Astrazeneca’s Breztri Share Top Ranking in 2024 Digital Marketing Competency Report | Morningstar

Janus Henderson Group PLC Acquires 85,502 Shares of AstraZeneca PLC (NASDAQ:AZN)

US regulator approves AstraZeneca's Imfinzi for small cell lung cancer By Proactive Investors

AstraZeneca: FDA Approves Imfinzi To Treat Adult Patients With Limited-stage Small Cell Lung Cancer

AstraZeneca’s Imfinzi Approved for Lung Cancer Treatment

AstraZeneca's Imfinzi gains FDA approval for small cell lung cancer By Investing.com

Health: FDA approves AstraZeneca's Imfinzi for limited-stage small cell lung cancer

AstraZeneca Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer By Investing.com

AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC - December 5, 2024 - Zacks.com

Here's Why Astrazeneca (AZN) is a Strong Momentum Stock - December 5, 2024 - Zacks.com

AstraZeneca's SWOT analysis: pharma giant's stock poised for growth amid challenges By Investing.com

AstraZeneca Appoints Iskra Reic as International EVP Amid Chinese Investigation; Stock Down 3.8% YTD

AstraZeneca Veteran Replaces Detained China Executive Leon Wang

AstraZeneca names Iskra Reic as EVP International By Investing.com